Medindia

X

Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase 3 MCRC Trial

Friday, February 26, 2010 Cancer News J E 4
Advertisement
Company Also Anticipates Phase 3 Results for Aptocine in HCC, Progress in Other Trials, and More Immune-Response Studies

Contacts

Llew Keltner, M.D., Ph.D.

President & CEO

425-957-8940

dr_llew@lsoncology.com

Robert M. Littauer

Vice President, Chief Financial Officer & Treasurer

425-957-8946

bobl@lsoncology.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Chemosensitivity/Resistance Assay Included as Part...
S
Doctors Applaud House Vote to Remove Anti-Trust Ex...